TechCheck+ The Future of Biotech Innovation and Investment 1/17/23

TechCheck

CNBC

Disruptors, Tech, Technology, Cnbc, Management, Business, Faang, Investing

4.5 • 66 Ratings

🗓️ 17 January 2023

⏱️ 20 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

CNBC's Meg Tirrell sits down with Dr. Christiana Bardon, co-managing director of BioImpact Capital, one of the world’s largest dedicated biotech investment firms dedicated to oncology therapeutics. The two discuss biotech innovation and investment in the space going into 2023, progress in areas such as obesity and Alzheimer’s, and the current regulatory environment for the industry.

Transcript

Click on a timestamp to play from that location

0:00.0	Hi everybody I'm Meg Terrell,
0:02.8	C. NBC Senior Health and Science reporter.
0:05.1	Joining us for a Tech Check Plus live stream today
0:07.9	is Dr. Christianna Barden, co-managing partner
0:10.8	of Bioimpact Capital.
0:12.2	Dr. Barton, it's great to have you with us.
0:14.4	Great to see you again.
0:15.3	Thanks for having me.
0:16.5	Well, I'm so excited to get to talk with you
0:18.2	in this format that gives us a little bit more time.
0:20.3	And I want to encourage everybody out there in the audience to submit questions.
0:23.9	We will get them to Dr. Barden and we're in for a really fantastic chat.
0:28.0	And that was a great time to connect because we're both just off this giant industry conference,
0:33.0	JP Morgan health care out in San Francisco.
0:36.1	People talk about this conference
0:37.4	is kind of setting the stage for the year
0:40.0	in biotech and health care.
0:43.2	What did you think the vibe was there
0:45.3	in terms of just sort of the sentiment
0:46.8	around how people are thinking about biotech
0:48.5	and health care more broadly?
0:50.2	Yeah, so first of all, you know,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from CNBC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of CNBC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.